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ABSTRACT. In this work, we demonstrate that the indole-oxazole-pyrrole framework of the 
breitfussin family of natural products is a promising scaffold for kinase inhibition. Six new 
halogenated natural products, breitfussin C – H (3 – 8) were isolated and characterized from the 
Arctic, marine hydrozoan Thuiaria breitfussi. The structures of two of the new natural products 
were also confirmed by total synthesis. Two of the breitfussins (3 and 4) were found to selectively 
inhibit the survival of several cancer cell lines, with the lowest IC50 value of 340 nM measured 
against the drug-resistant triple negative breast cancer cell line MDA-MB-468, while leaving the 
majority of the tested cell lines not or significantly less affected. When tested against panels of 
protein kinases, 3 gave IC50 and Kd values as low as 200 and 390 nM against the PIM1 and DRAK1 
kinases, respectively. The activity was confirmed to be mediated through ATP competitive binding 
in the ATP binding pocket of the kinases. Furthermore, evaluation of potential off-target and 
toxicological effects, as well as relevant in vitro ADME parameters for 3 revealed that the 














The human genome encodes 538 protein kinases, many of which are known to have fundamental 
roles in the molecular machinery controlling cell proliferation, survival and motility.1 As these 
processes are tightly regulated in normal cells, mutations causing dysregulation of kinase functions 
have been linked to a wide range of human malignancies.1-3 Several small-molecule kinase 
inhibitors have been marketed as drugs to treat a variety of different cancers, including leukemia 
and gastrointestinal tumors.4, 5 Inhibition of kinase activity using selective inhibitors provides a 
targeted treatment option with overall fewer side effects compared to traditional cancer 
chemotherapeutics.6 As most kinase inhibitors bind to the highly conserved ATP-binding pocket, 
development of selective inhibitors is challenging.7, 8 Accordingly, new scaffolds for selective 
kinase inhibition are in high demand.  
The breitfussins are a family of highly modified halogenated compounds comprising a unique 
indole-oxazole-pyrrole molecular framework. The first two compounds, breitfussin A and B (1 and 
2, Figure 1), were isolated from the cnidarian Thuiaria breitfussi and reported by us in 2012.9 
 
 
Figure 1. Structures of 1 – 8. 
 
 
Due to the low number of protons compared to heavy atoms (ratio 1:2), the structures of 1 and 2 
could not be elucidated by traditional methods alone, and atomic force microscopy (AFM) was 
used for the first time to elucidate the structure of unknown natural products.9 The structures of 1 
and 2 were later confirmed by total synthesis.10 Natural products consisting of oxazole-pyrrole11 or 
indole-oxazole12-14 moieties have previously been reported, however, the breitfussins are the first 
examples of natural products containing all three heterocycles. 
In the present work, we describe further chemical investigation of the organic extracts of T. 
breitfussi which led to the characterization of six new breitfussin analogues, breitfussin C – H (3 – 
8, Figure 1). Previously, bioactivity data (against one colon cancer cell line, bacteria- and fungal 
strains) for synthetically produced 2 has been reported by others,15, 16 while no bioactivity data has 
been reported for 1 and 3 – 8. We herein report on the cytotoxic activity against cancer cell lines 
and kinase inhibition profiles of 1 – 6. Further, we report the total synthesis of 3 and 4, which 
followed a similar strategy as reported for 1 and 2.10 Based on initial bioactivity data we performed 
an extended evaluation of the pharmacological potential of 3, and the potential of the core structure 
of the breitfussins as a new ATP-competitive kinase inhibitor scaffold was demonstrated. 
  RESULTS AND DISCUSSION 
   Isolation and Structural Elucidation 
   Specimens of T. breitfussi (475.6 g) were collected near Bjørnøya (Barents Sea) during a research 
cruise in 2011. We have previously reported the isolation and structure elucidation of 1 and 2 from 
a different T. breitfussi sample collected in the same area in 2007.9 Repeated purification of the 
organic T. breitfussi extract, using semi-preparative HPLC, led to the isolation of eight related 
compounds. Two of these were confirmed to be 1 and 2, while 3 - 8 were determined to be new 
breitfussin analogues.  
 
 
Breitfussin C (3) was isolated as a light brown powder. HRMS analysis suggested a molecular 
formula of C16H12BrN3O2 (12 degrees of unsaturation, m/z 358.0195 [M+H]
+, Δmmu = 0.4). The 
1H NMR spectrum of 3 (Table 1) recorded in DMSO-d6 displayed signals for seven aromatic 
protons with chemical shift values ranging from 7.79 to 6.18, two exchangeable protons at δH = 
11.85 and 11.64, as well as signals for one methyl group attached to a heteroatom at δH 3.91. The 
13C NMR spectrum of 3 (Table 2) confirmed the presence of 16 carbon atoms, including one 
methyl, seven methine and eight quaternary carbon atoms. The NMR spectra of 3 revealed 
chemical shifts in close agreement with those of 1 and 2. HMBC and HSQC experiments were used 
to determine the substitution pattern of the breitfussin skeleton of 3 (Figure 2). In the HMBC 
spectrum of 3, the methoxy protons (δH = 3.91) correlated with C-6 (δC 150.31). The downfield 
shift of C-6 in 3 is in agreement with the shift expected for a methoxylation in this position, and 
was also confirmed by a NOE between H-5 (δH = 7.38) and the methoxy protons (δH = 3.91). C-7 
(δC 107.1) was quaternary and attachment of the bromine atom to C-7 completed the planar 




Figure 2. Selected COSY, HMBC and NOE correlations obtained for 3. 
 
 
Breitfussin D (4) was isolated as a pale brown oil. Its molecular formula was found to be 
C16H12BrN3O2 (12 degrees of unsaturation, m/z 358.0197 [M+H]
+, Δmmu = 0.6) on the basis of 
HRMS analysis. The 1H NMR spectrum of 4 recorded in DMSO-d6 (Table 1) displayed two NH 
signals: H-18 at δH = 11.79 and H-1 at δH = 11.75, along with a signal for one methoxy group at δH 
3.95 and for seven aromatic protons with shift values ranging from δH 7.44 – 6.20. The 
13C NMR 
spectrum of 4 confirmed the presence of 16 carbon atoms including one methyl, seven methines 
and eight quaternary carbon atoms, further supporting the breitfussin carbon framework (Table 2).  
 
Table 1. Summary of 1H NMR (600 MHz, (CD3)2SO) data for 3 – 8.  
  3 4 5 6 7 8 
position δH (J in Hz) δH (J in Hz) δH (J in Hz) δH (J in Hz)
# δH (J in Hz)
# δH (J in Hz)
# 
1 11.64, d (2.6) 11.75, s 12.00, s 12.25, s 11.55, s 11.55, s 
2 7.79, d (2.7) 7.74, s 7.76, s  7.83, s 7.83, s 
5 7.38, s    7.42, s 7.42, s 
6  6.73, d (1.6) 6.73,d (1.6) 6.67, d (1.4)   
8 7.67, s 7.25, d (1.6) 7.26,d (1.6) 7.13, d (1.4) 7.70, s 7.77, s 
11 7.50, s 7.34, s 7.36, s 7.18, s 7.56, s 7.58, s 
15 
6.72, ddd 
(3.8, 2.4, 1.6) 
6.72,ddd 
(3.7, 2.0, 1.4) 
6.78,d (1.4) 
6.66, dd (3.7, 
1.5) 
6.74, d (3.8) 6.80, d (1.7) 
16 
6.18, dt (3.5, 
2.4) 
6.20, dt (3.5, 
2.3) 
 
6.16, dd (3.7, 
2.6) 
6.27, d (3.8)  
17 
6.94, td (2.6, 
1.5)  




6.91, dd (2.6, 
1.5) 
 7.13, d (1.7) 
18 11.85, s 11.79, s 12.30, s 11.77, s 12.61, s 12.20, s 
-OMe 3.91, s 3.95, s 3.95, s 3.75, s 3.95, s 3.95, s 




Table 2. Summary of 13C NMR (151 MHz, (CD3)2SO) data for 3 – 8. 
  3 4 5 6 7 8 
position δC, type δC, type δC, type δC, type δC, type δC, type 
2 124.7, CH 123.6, CH 124.0, CH 84.4#, C 125.0, CH 125.0, CH 
3 104.3, C 104.5, C 104.2, C 109.1#, C 104.1, C 104.1, C 
4 123.6, C 113.1, C 113.2, C 116.2#, C 123.5, C 123.5, C 
5 102.2, CH 154.0, C 154.1, C 152.6, C 102.2, CH 102.2, CH 
6 150.3, C 104.3, CH 104.4, CH 107.0, CH 150.4, C 150.4, C 
7 107.1, C 115.7, C 115.8, C 115.8, C 107.1, C 107.1, C 
8 116.6, CH 108.4, CH 108.5, CH 104.1, CH 116.6, CH 116.6, CH 
9 132.0, C 138.9, C 139.0, C 141.2#, C 132.0, C 132.0, C 
10 145.9, C 146.1, C nd 144.6, C 146.2, C 146.2, C 
11 120.5, CH 123.8, CH 123.1, CH 126.2, CH 120.5, CH 120.5, CH 
13 154.4, C 154.6, C 153.3, C 155.8, C 153.2, C 153.2, C 
14 120.3, C 120.5, C 121.4, C 120.3, C 122.2, C 121.3, C 
15 109.8, CH 109.6, CH 111.0, CH 109.6, CH 111.2, CH 111.1, CH 
16 109.7, CH 109.7, CH 96.3, C 109.5, CH 111.9, CH 96.4, C 
17 122.0, CH 121.8, CH 121.6, CH 122.0, CH 102.4, C 121.6, C 
-OMe 57.0, CH3 56.1, CH3 55.9, CH3 55.7, CH3 57.1, CH3 57.1, CH3 
#Acquired at pH 3.5 
 
Comparison of the 1H and 13C NMR spectra as well as HMBC coupling patterns of 4 with those 
of 1 – 3 confirmed the breitfussin skeleton. The downfield shift value of C-5 (δC 154.0) in 4 
indicated methoxylation in this position of 4. Correlations between the methoxy protons (δH = 3.95) 
and C-5 (δC 154.0) in the HMBC spectrum of 4 confirmed the position of the methoxy group. As 
 
 
for 3, C-7 (δC 115.7) was substituted with the bromine atom, thus giving the full structure of 4 as 
5-(6-bromo-4-methoxy-1H-indol-3-yl)-2-(1H-pyrrol-2-yl)oxazole. 
Breitfussin F (6) was isolated as a light brown powder. HRMS analysis gave a molecular formula 
of C16H11BrIN3O2 (12 degrees of unsaturation, m/z 483.9161 [M+H]
+, Δmmu = 0.4). The 1H NMR 
spectrum of 6 (Table 1) revealed the presence of a methoxy group (δH 3.75), four aromatic singlets 
(δH 7.18 – 6.16) and one NH proton H-18 (δH = 11.77). The NH-1 (δH 12.25) hydrogen could 
initially not be detected through NMR analysis. Due to the low amount of isolated material, only 
12 out of 16 carbon atoms in 6 gave detectable signals through 13C NMR analysis. The chemical 
shift of C-4 (δC = 116.0) was obtained through HMBC analysis, where it was found to correlate to 
H-6 (δH = 6.67) and H-8 (δH = 7.13). For C-2, C-3 and C-9, no cross peaks could be observed in 
the HMBC spectrum (Table 2). Through the 2D NMR experiments, partial structures of 6 could be 
unambiguously assembled: The pyrrole and the oxazole ring constituted one fragment and carbon 
atoms 4 to 8, including the methoxy group on the 5 position of the indole another fragment. This 
strongly indicates that 6 contains the characteristic breitfussin framework and leaves only one 
possibility for positioning of the iodine, i.e. on C-2 of the indole ring. An iodine at the C-2 position 
could explain the disappearance of the NH-1 proton as the iodine is expected to make the 
neighboring NH more acidic. Indeed, lowering the pH of the NMR sample to 3.5 shifted the 
equilibrium to protonating the nitrogen completely and the NH-1 did emerge at δH = 12.41 ppm. In 
this sample, the missing carbon shifts could be found at δC (C-2) = 84.4, δC (C-3) = 109.1, δC (C-
4) = 116.2 and δC (C-9) = 141.2. The structure of 6 was therefore assigned as 5-(6-bromo-2-iodo-
4-methoxy-1H-indo-3-yl)-2-(1H-pyrrol-2-yl)oxazole.  
Breitfussin G (7) and H (8) could not be chromatographically separated using semi-preparative 
HPLC and were isolated together as a pale yellow liquid. UHPLC-HRMS analysis of 7 and 8 gave 




Δmmu = 0.6; 8: m/z 435.9303 [M+H]+, Δmmu = 0.7) for both compounds. Comprehensive analysis 
of 1D (Table 1 and 2) and 2D NMR data, similar to the analysis performed for 6, confirmed the 
breitfussin skeleton of 7 and 8 to be related to 3. The methoxy group was in the 6 position, as in 3, 
but an extra bromine was positioned on the pyrrole. In 7, the bromine was placed on the C-17 based 
on H-15 and H-16 being vicinal as proved by a 3.8 Hz coupling and a strong ROEH-15/H-16. In 8, the 
bromine was placed on the C-16, resulting in the absence of any ROEH-15/H-16 and a weaker 
4JH-15/H-
17 of 1.7 Hz. The structure of 7 was therefore assigned as 2-(4-bromo-1H-pyrro-2-yl)-5-(6-bromo-
5-methoxyl-1H-indol-3-yl)oxazole and 8 was assigned as 2-(5-bromo-1H-pyrrol-2-yl)-5-(6-
bromo-5-methoxyl-1H-indol-3-yl)oxazole. 
 
The structures of re-isolated 1 and 2 were confirmed by comparing the analytical data with those 
previously reported by us (Table S1 and S2).9 
    
   Total Synthesis of 3 and 4 
   In order to carry out an extensive evaluation of the biological activity of 3, additional material 
was required. Previously we have reported the synthesis of 1 and 210 and the same strategy was 
applied for the synthesis of 3. This time, the total synthesis commenced by TIPS-protection of 5-
methoxyindole (9) following a literature procedure forming indole 10 (see SI).17-19 Selective 
bromination of 10 (Scheme 1) by directed ortho metalation20 proved to be difficult and several 
approaches including temporary introduction of a TMS group on C-321, 22 to induce steric 
hindrance,22 use of TBS instead of TIPS as protection group and the use of different lithiation 





Scheme 1. Total synthesis of 3 from indole 10a 
 
aReagents and conditions: (a) i) sec-BuLi, TMEDA, THF, 15 C to -5 C ii) Br(CH2)2Br, -5 C  
to rt (67%yield for mixture of 11 and 12); (b) ICl, pyridine, CH2Cl2, 0 C  to rt (97% yield); (c) i) 
(2-triisopropylsilyl)oxazol-5-yl)boronic acid pinacol ester, Pd(dppf)Cl2, K3PO4, toluene/H2O, 80 
C, ii) 10% aq. HCl, THF, 0 C (62% yield over 2 steps); (d) i) LiHMDS, THF, -78 C ii) I2, -78 
C (31% yield for 15, 47% yield for mixture of 16 and 17); (e) N-Boc-pyrrole-2-boronic acid, 
Pd(dppf)Cl2CH2Cl2, Cs2CO3, dioxane/H2O (66% yield); (f) i) TFA, CH2Cl2, 0 C to rt, ii) TBAF, 
THF (68% yield over 2 steps). 
 
   Eventually we found that using sec-BuLi/TMEDA followed by a reaction with 1,2-bromoethane 
gave a 2:3 mixture of 6-bromoindole 11 and 4-bromoindole 12 in 67% combined yield. 11 could 
then be isolated in pure form in 14% yield by crystallization from hexane. 6-Bromoindole 11 could 
 
 
then be iodinated to give 13 in high yield, which was subsequently submitted to the optimal 
coupling conditions identified in our previous synthesis of 1 and 2. Treating the cross-coupling 
product directly with aqueous HCl resulted in selective deprotection of the TIPS group in 2-position 
on the oxazole giving oxazole 14 in good yield. In our earlier synthesis of 1 and 2, we could only 
successfully couple onto a 2,4-diiodo oxazole derivative and not the 2-iodo oxazole derivative, thus 
2,4-diiodo oxazole 15 was the target for the next step. The iodination of 14 however proved to be 
sluggish, and similarly as reported earlier for the iodination en route to 1 and 2,10 we ended up with 
a mixture of the desired diiodo product 15 in 31% yield in addition to substantial amounts of mono-
iodinated oxazoles 16 and 17 (47% combined yield of 16 and 17). Mono-iodinated oxazoles 16 and 
17 were not separable by flash chromatography and re-submitting a mixture of 16 and 17 to the 
reaction conditions gave 15 in 61% yield. This provided sufficient amounts of the desired material 
and further Suzuki-Miyaura cross-coupling of 15 with Boc-protected 2-pyrrolyl boronic acid gave 
the complete indole-oxazole-pyrrole scaffold 18 in good yield. Finally, 18 was submitted to 
simultaneous acid-mediated Boc-deprotection and deiodination followed by TIPS deprotection to 
give 3 in 1.1% yield over 9 steps. Deiodination and deprotection of the earlier reported intermediate 
19 (Scheme 2)10 gave natural product 4, which has been prepared previously by another group 
using a different approach.16 
Scheme 2. Synthesis of 4a 
 
aReagents and conditions: (a) i) TFA, CH2Cl2, 0 C to rt, ii) TBAF, THF (77% yield over 2 steps). 
 
 
   In vitro Cytotoxic Activities of 1 – 6 
   The  cytotoxic properties of 1 – 6 were evaluated against seven cancer cell lines (MCF-7, MDA-
MB-468 and SK-BR-3: breast adenocarcinoma, HT-29: colon adenocarcinoma, MOLT-4 and MV-
4-11: leukemia and A2058: melanoma,) and one non-malignant cell line (MRC-5: lung fibroblasts) 
(Table 3) using the MTS assay.23 Compounds 7 and 8 were not evaluated, as they were isolated as 
a mixture.  
 
Table 3. IC50 (µM) of 1 – 6 against seven malignant and one non-malignant cell line.  
Comp 
IC50 (µM) ± SD 
MCF-7b MDA-MB-468b SK-BR-3b HT-29c MOLT-4d MV-4-11e A2058f MRC-5g 
1 naa na na na na na na na 
2 na na na na na na na na 
3 8.5 ± 0.2 na na 7.1 ± 0.2 9.9 ± 0.4 4.4 ± 0.5 na 7.1 ± 0.6 
4 3.9 ± 0.3 na na na na na na na 
5 na na na na na na na na 
6 na na na na na na na na 
ana: not active (IC50 > 10 µM); 
bMCF-7, MDA-MB-468 and SK-BR-3: breast adenocarcinoma; 
cHT-29: colorectal adenocarcinoma; dMOLT-4: acute lymphoblastic leukemia, eMV-4-11: 
myelomonocytic leukemia; fA2058: melanoma; gMRC-5: non-malignant lung fibroblasts, all of 
human origin.
 
While 1, 2, 5 and 6 showed no significant activity towards these cell lines, 3 and 4, displayed 
cytotoxic activities. Compound 3 reduced the viability of MCF-7, HT-29, MOLT-4, MV-4-11 and 
MRC-5, and 4 affected the viability of MCF-7. Only IC50 values under 10 µM were measurable, as 
the compound precipitated at around 20 µM in this assay setup, interfering with the readout of the 
experiments. Through microscopic evaluation of test wells it was however clear that the sensitivity 
 
 13 
of the cells towards the compounds varied significantly. For example, compound 3 had no 
observable effect towards A2058 viability at concentrations up to 100 µM. 
To evaluate whether the activities of 3 and 4 were time-dependent, IC50 values for the compounds 
were determined after 4, 24, 48 and 72 h of exposure against two cell lines (3 against HT-29, 4 
against MCF-7). Exposure of the affected cell lines to 3 and 4 gave decreasing IC50 values with 
increasing exposure times (Figure S3).  
 
The Breitfussins as Kinase Inhibitors 
   To identify potential cellular targets of the breitfussins, 1, 3 and 4 were tested against a panel of 
140 kinases at the International Centre for Kinase Profiling (ICKP) in Dundee (Scotland, UK) using 
activity-based radioactive (33P-ATP) filter-binding assays.24 Compound 1 was tested at 50 µM, 3 
at 50, 5 and 1 µM and 4 at 5 and 1 µM (Table S3). At 50 µM, 1 was the least active of the tested 
compounds. Three kinases had residual enzyme activities (RA) between 50 and 30% and two below 
30% (AMPK: 28%, TSSK1: 21%). Compound 1 was therefore not tested at lower concentrations. 
At 50 µM, 3 gave RAs between 50 and 30% for 23 kinases, between 30 and 10% for 24 kinases 
and lower than 10% for 7 kinases (RIPK2: 10%, ERK8: 9%, GCK: 7%, TAK1: 7%, Aurora B: 6%, 
MLK1: 5% and PIM1: 2%) (Figure 3A). At 5 µM, the number of kinases inhibited by 3 decreased 
and at 1 µM, 3 gave RAs between 50 and 30% for 5 kinases (NUAK1: 46%, RIPK2: 41%, TAK1: 
35%, Aurora B: 33%, GCK: 31%), between 30 and 10% for 2 kinases (MLK1: 26%, MLK3: 20%) 
and lower than 10% for 2 kinases (PIM1: 6%, PIM3: 7%) (Figure 3B). At 5 µM, 4 affected 3 
kinases to give RAs between 50 and 30%, 5 kinases between 30 and 10% and 2 kinases to RAs 
lower than 10% (MLK1: 7%, MLK3: 7%), while at 1 µM, no kinase had RAs below 10%, and one 





Figure 3. Kinome inhibition data of 3 at 50 (A) and 1 µM (B) against 140 kinases. Disc sizes and 
colors are encoding the level of residual activity as shown in figure key. 
    
    Selectivity of Breitfussin Kinase Inhibition 
    From the data obtained through the kinase inhibition experiments, it was possible to draw Lorenz 
curves and calculate the Gini coefficient (GC)25 for 3 at 50, 5 and 1 µM and for 4 at 5 µM. The GC 
of 3 rose from 0.432 at 50 µM to 0.484 at 5 µM, and 0.605 at 1 µM. The GC for 4 at 5 µM was 
0.529. The GC for 4 at 1 µM could not be calculated, as too few kinases were affected. The GC 
score of 0.605 for 3 at 1 µM is high for a natural product whose scaffold has not been optimized 
through synthesis. It is worth mentioning that lapatinib, gefitinib and sunitinib, which are all 
marketed kinase inhibitors used to treat various types of cancers, have GC scores of 0.57, 0.65 and 
0.67, respectively, when assayed against 317 kinases at 10 µM.26, 27 GC scores do not take into 
account selectivity for subsets of related kinases, and the scores cannot be directly compared to 
 
 15 
other compounds unless tested under the same conditions (same concentration, same panel of 
kinases etc.). However, it provides an overall indication of specificity and indicates that 3 is a 
narrow-spectrum kinase inhibitor. 
 
   IC50 of 1 – 6 Against Relevant Kinases 
Based on the kinase inhibition profiling of 3 and 4, 13 kinases were selected for determination 
of IC50 values against 2 – 6 (Table 4). As 1 did not significantly inhibit any of the kinases at 50 
µM, it was not included in the IC50 determination. PIM2 and Aurora B were included to highlight 
the selectivity of inhibition of the closely related kinases PIM1 and PIM328 and Aurora A29, 
respectively. The difference in the kinase inhibition potency of 1 – 6 correlated well with the cancer 
cell cytotoxic data (MTS assay) recorded for the same compounds. Although we have not observed 
a functional correlation of the inhibition of a specific or single kinase with antiproliferative activity 
yet, breitfussin analogs inhibiting multiple kinases in vitro have higher potency in the cytotoxicity 
assays. This is beyond this initial characterization of the breitfussins as kinase inhibitors and it is 
going to be the task of future optimization chemistry to generate highly selective analogs from the 
breitfussin scaffold, which are expected to show a clear functional correlation in vitro and in 
functional cellular assays. Compound 3 was the most potent inhibitor, giving IC50 values as low as 
200 nM ± 50 (PIM1). Based on the results from the in vitro  cancer cell cytotoxic and kinase 
inhibition profiles of 1 – 6, 3 was selected for further studies to evaluate the pharmacological 






Table 4. IC50 determination of 2 – 6 against 13 kinases nominated through kinase profiling of 3 
and 4. 
aNot active (IC50 > 50 µM) 
 
      Extended Kinase Inhibition Profile for 3 
   The binding affinities of 3 were tested at 10 µM against 468 kinases and pseudo kinases found 
in the DiscoverX ScanMax panel (Figure 4, Table S4). In these active-site directed competition 
binding assays, a kinase ligand is immobilized to a solid support. The amount of kinase bound to 
the immobilized ligand in the presence and absence (control) of 3 were quantified, and the affinity 
of 3 to the kinase active site was reported as percent of control (PoC).30, 31 At 10 µM, 3 gave PoC 
values lower than 35% for 30 kinases. The strongest affinity of 3 was observed against the three 
 Compound IC50 (µM) 
Kinase 1 2 3 4 5 6 
DYRK1A naa na 2.3 ±0.2 na na na 
ERK8 na na 1.0 ±0.1 46 ±7 na na 
PIM1 na na 0.2 ±0.05 0.9 ±0.01 43 ±12 18 ±9 
PIM2 na na 11 ±2 22 ±3 na na 
PIM3 na na 1.8 ±0.1 3.7 ±0.8 na na 
SIK3 na na 1.2 ±0.1 na na na 
GCK na na 0.6 ±0.06 1.2 ±0.1 na 40 ±5 
TAK1 na na 1.2 ±0.1 1.0 ±0.1 36 ±15 18 ±7 
MLK1 na na 0.6 ±0.12 0.9 ±0.04 22 ±2 21 ±7 
MLK3 na na 0.6 ±0.05 0.5 ±0.05 23 ±2 19 ±2 
RIPK2 na na 1.1 ±0.2 na na na 
Aurora A na na 22 ±6 na na na 
Aurora B na na 0.8 ±0.02 0.9 ±0.23 7.8 ±0.2 31 ±3 
 
 17 
related Ca2+/calmodulin-dependent protein kinases MYLK4, DRAK2 and DRAK1, with PoC 
values of 0.25, 1.2 and 2.9%, respectively. PIM1, the kinase against which the lowest IC50 value 
for 3 was measured in the ICKP activity assay (IC50 = 0.2 µM), gave a PoC of 9.5%. Compound 3 
had stronger affinity towards PIM1 than PIM2 and PIM3 (PoC: PIM3 = 21%, PIM2 = 54%). The 
relative affinities of the PIM kinases correlated well with the IC50 values found in the activity assays 
(IC50: PIM3 = 1.8 µM, PIM2 = 11 µM).  
 
Figure 4. Kinome binding affinity data of compound 3 at 10 µM against 468 kinases. The disc 
sizes encode the level of residual activity as shown in the figure key. 
 
Furthermore, the Kd values of 3 against the 19 kinases with lowest PoC values were determined 
(Table 5). When comparing the results obtained for 3 from the ICKP and the DiscoverX panels, 
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two kinases were found to be among the most sensitive candidates in both assays: PIM1 and PIM3 
(PIM1: IC50 = 200 nM, Kd = 1.2 µM and PIM3: IC50= 1.79 µM, Kd = 4.7 µM). All the 11 remaining 
kinases, for which IC50 values were determined at ICKP, were tested at 10 µM at DiscoverX, 
however, 3 did not bind strong enough to these for Kd determination to be prioritized (PoC at 10 
µM: DYRK1A: 75%, ERK8: 67%; SIK3 (QSK in DiscoverX panel): 94%; GCK (MAP4K2 in 
DiscoverX panel): 72%; TAK1: 70%; MLK1: 59%; MLK3: 56%; Pim2: 54%; RIPK2: 57%; 
AuroraA: 80%; AuroraB: 50%). The remaining enzymes against which the Kd values of 3 were 
determined in the DiscoverX panel, were not available in the ICKP panel. Disagreement between 
binding- and activity based assays are not uncommon and can be explained by the use of different 
constructs, expression systems, purification protocols and assay conditions.32 The affinity of 3 
towards kinases and the selective nature of this interaction, was however confirmed through the 
data obtained from DiscoverX. 
 
Table 5. Kd values of 3 against the DiscoverX kinases with strongest binding affinities.  
Kinase Kd (µM) Kinase Kd (µM) Kinase Kd (µM) 
DRAK2 0.39 ±0.04 STK35 1.3 ±0.1 DRAK1 2.8 ±1.3 
MYLK4 0.43 ±0.07 IRAK3 1.7 ±0.2 PIK4CB 2.9 ±0.3 
GAK 0.44 ±0.02 TYK2* 1.8 ±0.1 RIOK1 2.9 ±1.8 
JAK1* 1.0 ±0.1 DCAMKL3 1.8 ±0.2 CSNK1E 3.3 ±0.2 
PIKFYVE 1.0 ±0.1 CIT 2.7 ±0.1 PIM3 4.7 ±0.3 
BIKE 1.1 ±0.1 STK36 2.7 ±0.1 FLT3 (N841I mutant) 8.9 ±4.2 





Several of the kinases inhibited by or binding to 3 are validated as anticancer targets. To name a 
few, the PIM kinases are known drivers in many cancers, including triple negative breast cancer.33 
Mutants of FLT3 kinase occur in approximately 30% of all acute myeloid leukemia cases34 and 
ERK8 and AuroraB are highly expressed in several human cancers, including lung cancer.35, 36 The 
exact cellular target(s) responsible for the observed cytotoxic activities of 3 remain to be 
determined and may be due to pan-kinase inhibition.  
 
       Selective Cytotoxic Activity of 3 
  To get more information on the selectivity of 3 against a broader panel of cell lines, IC50 
values of 3 were determined against 88 cancer cell lines and proliferating peripheral blood 
mononuclear cells (PBMCs) in the OncoLead cell panel using a sulforhodamine B protein 
staining assay technique (Figure 5 and Table S6).37 The cell lines included in this panel covers 
multiple cancer types (overview in figure 5) and the IC50 values against the 10 most affected cell 
lines are listed in Table 6. The results from this screening confirmed the potent and selective 
cytotoxic activity of 3 with activities at low µM/sub-µM IC50 concentrations (lowest IC50 = 0.34 
µM). In comparison, the lowest reported IC50 value of the kinase inhibitor roscovitine, which is 
currently under clinical development as an anticancer agent, was 4.9 µM in a comparable assay 
setup.38 In total, 48 out of the 88 cell lines were affected to some extent by exposure to 3. The 
most striking results from these experiments are the ability to specifically inhibit the viability of 
selected breast cancer cell lines. Most potently inhibited cell line was the drug-resistant triple 
negative breast cancer (TNBC) cell line MDA-MB-468 (IC50 = 340 nM). In our in-house MTS 
based cancer cell cytotoxic assay the MDA-MB-468 cell line was significantly less affected 
(IC50 value > 10 µM). While the MTS assay is considered a precise and specific in vitro assay  
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for measuring cytotoxic activity of investigated agents, it has been shown that colorimetric 
assays may underestimate anti-proliferative effects.39 For example, damaged mitochondria may 
still be able to reduce the dye and investigated agents may interfere with mitochondrial 
dehydrogenase activity.40, 41  This discrepancy is thus most likely due to the difference in assay 
technique. The following breast cancer cell lines were also affected: MCF-7 (IC50 = 0.77 µM), 
MT3 (IC50 = 0.93 µM), SK-BR-3 (IC50 = 1.53 µM), JIMT1 (IC50 = 4.17) and the TNBC cell line 
HS578T (IC50 = 5.22 µM).  
 





Table 6. The 10 cancer cell lines in the OncoLead panel that were most affected by 3. 
Cell line Origin IC50 (µM) Z-score 
MDA-MB-468 Breast 0.34 -3.87 
MCF-7 Breast 0.77 -2.47 
MT3 Breast 0.93 -2.35 
PLCPRF5 Liver 1.5 -1.6 
SK-BR-3 Breast 1.5 1.1 
NCIH460 Lung 2.0 -1.0 
A673 Muscle 2.2 -1.0 
JAR Placenta 2.3 -0.8 
RDES Bone 2.5 -0.9 
HEPG2 Liver 3.0 -0.6 
 
Compound 3 had no or significantly lower effect against the remaining breast cancer cell lines: 
BT20, MDA-MB-231 and MDA-MB-436 (IC50 values > 30 µM). The non-malignant human 
PBMCs and 39 cancer cell lines were not affected even at the highest dose of 30 µM of 3. 
Such a differential inhibition profile in a broad cancer cell panel is typically observed when one 
or a few molecular mechanisms of inhibition are present in the sensitive cell lines. Therefore, it is 
our assumption that 3 inhibits one or a few proliferation relevant kinases, which are important 
drivers of cancer formation.  
   Natural product often serve as lead templates that are subjected to structural optimization to 
generate clinically useful structures.42 Selective and potent activity against cancer cells (IC50 values 
< 1 µM) and inhibition of kinases in the nM range show the value of the breitfussin scaffold as an 
excellent starting point for the development of an anticancer compound. In comparison, rohitukine, 
a flavonoid alkaloid initially isolated Amoora rohituka, gave IC50 values of 300 ± 15 nM against 
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the kinase CDK-9 and GI50 values of 10 – 28 µM against five cancer cell lines.
43 Medicinal 
chemistry efforts based on the rohitukine scaffold rewarded two new promising clinical candidates, 
flavopiridol and riviciclib.44 Both are currently undergoing clinical evaluation as anticancer agents 
targeting several kinases where the primary mechanism of action is believed to be through CDK-9 
inhibition.44 Riviciclib has an IC50 value of 20 nM against CDK-9.
43 
    
   Mode-of-Action of the Breitfussins against the Kinases 
   Many natural product kinase inhibitors or derivatives thereof, like roscovitine, as well as 
synthetic small molecule kinase inhibitors inhibit their targets by competition with ATP.7, 8 The 
ICKP and DiscoverX assay technologies are biased towards ATP competitiveness as mode-of-
action. We therefore tested the ability of 1 - 4 to bind to the ATP binding pocket employing two 
different tracer displacement assays. As the assays herein used to measure ATP competitiveness 
are based on binding affinity, DRAK2 and DRAK1, to kinases with closely related structures,45 
were chosen as model kinases at they display strong binding affinity towards 3 (Kd (µM): DRAK2 
= 0.39 ±0.04, DRAK1 = 2.8 ±1.3).  
 
   The cell free ATP-competitive tracer displacement assays46 are based on the binding and 
displacement of the Alexa Fluor 647-labelled ATP competitive kinase tracer to glutathione S-
transferase (GST)-tagged DRAK1 and DRAK2. Tracer binding was detected by using europium 
(Eu)-labelled anti-GST antibodies. Simultaneous binding of both fluorescent tracer and antibody 
to the GST-tagged kinase generated a fluorescence resonance energy transfer (FRET) signal. When 
adding an inhibitor, which competes with binding of the tracer, a loss of the FRET signal was 
observed. Using this assay, 3 and 4 were shown to bind to the ATP binding pocket (Table 7). To 
evaluate the binding of 1 – 4 to the ATP binding site within living permeabilized cells (cells 
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permeabilized using digitonin), the NanoBRET kinase target engagement assay was used.47 This 
target engagement assay is based on an energy transfer technique designed to measure molecular 
proximity in living cells and cell lysates. This intracellular kinase assay measures the apparent 
affinity of test compounds by competitive displacement of a tracer molecule reversibly bound to 
the ATP binding site of a kinase fused with the NanoLuc luciferase. In the first step of this assay, 
a fixed concentration of tracer was added to cells expressing the desired NanoLuc fusion protein 
to generate a BRET reporter complex. Introduction of competing compounds results in a dose-
dependent decrease in NanoBRET energy transfer allowing for quantitation of the intracellular 
affinity of the target protein for the test compound. In this assay, 2 - 4 were shown to bind to the 
ATP binding pocket of DRAK1 and DRAK2 (Table 7).  
 
Table 7. The ATP competitiveness of compounds 1 – 4. 
 IC50 (µM) 
 DRAK1 DRAK2 
Comp. Cell free tracer displacement assay 
1 >10 >10 
2 >10 >10 
3 4.6 9.8 
4 9.6 >10 
 Intracellular tracer displacement assay 
1 >10 >10 
2 >10 3.3 
3 3.0 0.5 




  In both assay formats, selected breitfussins were shown to bind to the ATP binding site of the 
selected kinases by displacing the tracers from the ATP binding sites of DRAK1 and DRAK2. 
 
   Docking of 3 to the ATP-binding pocket of PIM1 
To complete the scenario of identifying the ATP binding pocket as the site of interaction between 
3 and the kinases, 3 was docked manually and computationally using Glide into a cocrystal 
structure of PIM1 (Protein Data Bank access code 4K1B) (Figure 6). Several binding modes were 
obtained, submitted to a short molecular dynamics run, and minimized. The pyrrole and indole N-
H groups are complementary to the two C=O groups available as hydrogen bond acceptors in the 
hinge region of PIM1. The pyrrole and indole N-H groups form hydrogen bonds to the hinge 
backbone C=O groups of Pro123 and Glu121. The indole is stacked between lipophilic residues 
and does not interfere with the gate keeper residue (Leu120). Through this experiment, we were 
able to determine binding to the ATP-binding pocket as mode-of-action for 3.  
 
Figure 6. Binding mode of 3 with the ATP-binding pocket of PIM1 (PDB: 4K1B). Compound 3 
is shown with yellow carbon atoms, the hinge backbone carbon atoms of PIM1 are in green 
(Pro123, Arg122, Glu121, Leu120). A water molecule present in 4K1B is replaced by the pyrrole 
and is shown as a red sphere. A: Surface representation of the ATP-binding pocket of PIM1 with 
compound 3. B: Detailed view of the interaction between the PIM1 hinge residues and 3.   
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   Potential Off-Target Effects of 3 
   To evaluate potential off-targets interactions for 3, a diversity panel screen at 10 µM was 
performed using the Cerep Panlabs diversity panel (previous version now known as the Eurofins 
discovery safetyscreen panel). The panel was designed to assess potential adverse effects of a lead 
compound. In total, only 16 out of 98 targets were affected to the point where percentage inhibition 
of control values (phosphodiesterase type 4D2 and phosphodiesterase type 5, Figure 7) and specific 
binding (rest) were defined as active (above 50%). The remaining 82 targets were below 50% 
(Table S5A and B). On the list of affected targets, the majority were receptors. In addition, a 
transporter (norepinephrine transporter) and two enzymes (phosphodiesterase type 4D2 and 5) 
were also affected. As most of the targets will not affected at concentrations corresponding to the 
IC50 or Kd values for the on-target effects, 3 is considered as having promising selectivity. 
 
 
Figure 7. Potential off-targets (>50%) of 3 tested at 10 µM in the Cerep Panlabs diversity profile 




   In vivo Toxicity of 3  
   The toxicity of 3 against zebrafish embryos was evaluated by recording survival and toxic 
phenotype formations, including cardiac edema, scoliosis, tail degeneration, necrosis and 
generalized edema. The assay was conducted at the BioReperia laboratory. Zebrafish embryos are 
considered a powerful tool to assess toxicity as it allows for whole-animal investigation.48 At 72 h 
exposure, the concentration resulting in 50% lethality (LD50) was 1.4 µM. This value is four-fold 
higher than the most potently inhibited cell line in the OncoLead panel. Toxic phenotypes were 
only evaluated on living embryos, and the results are given as the percent of embryos not exhibiting 
the toxic phenotype (Figure 8 and Table 8).  
 






Table 8. Embryos being healthy and not exhibiting the indicated issues of toxicity or death, 
expressed as % of all living embryos after being exposed to 3 for 72h.  
 Unaffected embryos (%) 
Conc. (µM): 1396 140 14 1.4 0.1 0 
Toxicological issue       
Survival 0,0 0,0 5 45 100 95 
Heart edema NAa NA 100 100 95 100 
Scoliosis NA NA 0 89 95 100 
Tail degeneration NA NA 0 100 100 100 
Necrosis NA NA 0 0 100 100 
General edema NA NA 100 100 100 100 
aNA: Not available 
 
In general, heart edema and generalized edema were not observed to any significant degree in 
response to any non-lethal concentration of 3. Scoliosis and tail degeneration were observed in all 
embryos exposed to the highest non-lethal concentration of 3 (1.4 µM). Compound 3 was poorly 
soluble in the assay media (PTU-E3 water). Precipitated 3 was evident for the highest test 
concentrations (1396 (data not shown in Figure 8), 140 and 14 µM). 
 
   Determination of In Vitro ADME Parameters of 3 
   Compound 3 was profiled in an in vitro ADME assay panel to address its aqueous kinetic 
solubility, permeability through artificial membranes (PAMPA), metabolic stability under 




Table 9. In vitro ADME parameters of 3. 
Assay Output 
Human MSa phase I Clint 14 µL/min/mg 
Mouse MS phase I Clint 47 µL/min/mg 
Human MS phase II 92 % remaining after 1 h at 5 µM 
Mouse MS phase II  100 % remaining after 1 h at 5 µM 
Membrane permeability 23 Flux [%] 
Human plasma protein binding  0.3 % unbound at 5 µM 
Mouse plasma protein binding 0.3 % unbound at 5 µM 
Human Plasma Stability 83 % remaining after 1 h at 5 µM 
Mouse Plasma Stability 84 % remaining after 1 h at 5 µM 
Solubility at pH 7.4 156 µM 
aMS: Microsomal stability 
 
In all these assays, 3 was found to have favorable properties as a lead compound. Particularly, 
the moderate intrinsic clearance (Clint) value of 47 µL/min/mg obtained in the presence of mouse 
liver microsomes and the acceptable stability of 85% in mouse plasma predicts good exposure in 
mice. Mice will thus be a suited species for proof-of-concept studies in the future. In this regard, it 
will be interesting to determine the pharmacokinetic parameters in mice as a next step to see how 
well the in vitro profile correlates with the in vivo ADME properties.   
 
   CONCLUSION 
   The results from this investigation into the cytotoxic activities, kinase inhibition and ADME and 
toxicological properties of the breitfussins (3 in particular) clearly show the potential of the 
breitfussin scaffold for further development of lead compounds primarily with antiproliferative 
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activity. Even as non-modified natural products, the breitfussins show preferential binding to 
kinases and inhibition of cell viability at promising potency and selectivity. We consider the 
breitfussin to be an interesting scaffold of narrow-spectrum kinase inhibitors. Further exploration 
of the series might quickly lead to the generation of more selective inhibitors of the indicated kinase 
subfamilies.  
 
   EXPERIMENTAL SECTION 
Materials and methods for natural product isolation and structure elucidation 
General experimental procedures 
A Waters 600 Pump monitored by a 2996 Photodiode Array UV detector and a 3100 single 
quadrupole MS were used for mass guided preparative HPLC over a Waters XSelect CSHTM Prep 
Fluoro-Phenyl column (5 µm 10*250 mm). A Waters LCT Premier Time-of-Flight mass 
spectrometer with a Waters Acquity UPLC was used for acquisition of high-resolution mass data. 
The purity of key compounds (isolated 3 and 4 and synthetically produced 3) were measured using 
UHPLC-UV analysis and calculated using the UV purity tool in the Waters UNIFY Scientific 
Information System software. The purity was determined to be ≥95% for all key compounds. 
 
Reagents and materials 
HPLC grade acetonitrile (ACN) and methanol (MeOH) (Chromasolve®, for preparative HPLC), 
LC-MS grade ACN (Chromasolve®, for LC-MS analysis) and reagent-grade formic acid (≥98%) 
were purchased from Sigma- Aldrich (Steinheim, Germany). Ultra-pure water was prepared using 
a Millipore Milli-Q purification system (Bedford, MA, USA). Deuterated DMSO and methanol 
were purchased from Sigma-Aldrich (Steinheim, Germany). Roswell Park Memorial Institute 
(RPMI, Merck KGaA), Earle’s minimal essential medium (E-MEM, Merck, Germany), 
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Dulbecco’s modified Eagle’s medium (D-MEM, Thermo Fisher Scientific), McCoy’s 5A 
(Biowest, France), Leibovitz L15 Medium (L15, Biowest, France) and Iscove Basal Medium with 
stable glutamine (Merck, Germany) cell media were used. D-MEM and RPMI were supplied with 
10% fetal bovine serum (FBS, Merck) and 5 mL L-alanyl-L-glutamine (200 mM, Merck, 
Germany). E-MEM was supplied with 10% FBS, 5 mL L-alanyl-L-glutamine, 5mL non-essential 
amino acids (100x, Merck, Germany), 5 mL sodium pyruvate (100 mM, Merck, Germany) and 5 
mL sodium bicarbonate (7.5%, Merck, Germany). McCoy’s 5A and Iscove basal medium were 
supplied with 10% FBS. L15 was supplied with 10% FBS and 5 mL sodium bicarbonate. All media 
were supplied with gentamycin (10 µg/mL, Merck, Germany).  
 
Biomass collection 
Specimens of the cnidarian Thuiaria breitfussi (class Hydrozoa, order Leptothecata, family 
Sertulariidae) were collected with a triangular bottom scrape in September 2011 at Bjørnøya, 
Svalbard (79.0293 N, 20.8574 E, at 48 m depth). The organism was identified by Robert A. 
Johansen, the Norwegian national biobank (Marbank) and a voucher specimen (reference number: 
M13031) was deposited at Marbank, Tromsø, Norway. 
 
Isolation of breitfussin A – H (1 – 8) 
The frozen specimens of T. breitfussi (475.6 g) were freeze-dried and minced. The resulting mass 
(96.6 g) was extracted twice with water (24 h and 30 min, respectively) at 5 °C in the dark. After 
centrifugation the remaining sediment was freeze-dried, minced, and extracted twice with a 1:1 
(vol:vol) mixture of dichloromethane and MeOH and filtrated. The filtrate was dried, resulting in 
6.0 g organic extract. An aliquot of the organic extract (4.3 g) was partitioned between 150 mL 
hexane and 150 mL 90% MeOH three times to remove very lipophilic compounds. The pooled 
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MeOH fractions were dried under reduced pressure and redissolved in 13 mL MeOH. Aliquots of 
this solution were injected onto a fluoro-phenyl column (gradient of 45 to 65% of ACN (aq) over 
20 min, 6 mL/min). In the end, eight breitfussins were isolated in amounts that enabled structure 
determination by NMR. Out of these, six were pure compounds: 1 (4.2 mg), 2 (3.1 mg), 3 (7.3 mg), 
4 (2.2 mg), 5 (2.0 mg), 6 (1.9 mg). We were not able to separate 7 and 8, and a mixture of the two 
(1.33 mg in total) was submitted to NMR analysis. 
 
NMR analysis of isolated 3 - 8 
All NMR data were acquired on a Varian/Agilent Inova spectrometer operating at 599.934 and 
150.863 MHz for 1H and 13C respectively, using a cryogenically cooled inverse detection HCN 
probe with enhanced proton channel (2nd generation). All spectra were acquired at 298 K in 
DMSO-d6. Data acquired in DMSO-d6 was referred to the residual solvent peak of DMSO-d6, 
1H 
= 2.504 and 13C = 39.98 ppm. Typically, 16-32k data points were acquired for the 1D 1H 
experiments using 90° reading pulses, 5 seconds relaxation delay and 8-32 transients. For the 2D 
phase insensitive gradient selected COSY experiments, 1440 x 200 complex data points were 
acquired using 4-8 transients. Data matrices of 1440 x 200 and 1440 x 256 complex points were 
acquired for the gradient selected edited HSQC and absolute value HMBC respectively, using 8 to 
32 transients. ROESY spectra were acquired as 1440 x 256 complex data points and 8 transients, 
with spinlock duration of 300 ms at 36 dB. For carbon 1D spectra, 32k complex data points were 
acquired, using 45-90° reading pulses, 1-5 seconds relaxation delay and 10000-20000 transients 
applying 1H decoupling during both relaxation and acquisition time. All spectra were acquired at 
298 K in both DMSO-d6 (Sigma-Aldrich) and methanol-d4 (Sigma-Aldrich) using sweep widths of 
9600 and 30200-37800 Hz for 1H and 13C, respectively. Two-dimensional experiments were 
acquired using the grad-90-grad option with 2 ms homospoil gradient time at 5796 Hz. Data 
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acquired in DMSO-d6 was referenced to the residual solvent peak of DMSO-d6, 
1H = 2.504 and 
13C = 39.98 ppm. 
 
Synthesis of 3 and 4 
General 
All reactants, reagents and solvents were purchased from Sigma-Aldrich and used as delivered 
unless otherwise stated. Compound 19 was prepared as previously described.10 Moisture sensitive 
reactions were carried out under an argon atmosphere in oven-dried (130 °C) equipment that had 
been cooled down under vacuum. Solvents used for moisture sensitive reactions were obtained 
from an anhydrous solvent delivery system (SPS-800 system from M. Braun GmbH, Garching, 
Germany). Anhydrous THF was obtained from the SPS-800 or from a sodium/benzophenone still. 
Flash chromatography was performed using silica gel from Merck (Silica gel 60, 0.040 – 0.063 
mm) or Grace GmbH (35-70 micron). TLC analyses were performed on aluminium sheets coated 
with Merck TLC silica gel 60 F254 and visualization was achieved by using ultraviolet light (254 
nm) or a solution of phosphormolybdic acid in ethanol. The NMR-experiments were recorded on 
a Bruker Ascend 400 or a Bruker BioSpin AV500 at ambient temperature. 1H and 13C chemical 
shifts (δ) are reported in ppm with reference to the solvent residue peak (CDCl3: δH = 7.26 and δC 
= 77.16; DMSO-d6: δH = 2.50 and δC = 39.98). All coupling constants are given in Hz. ESI-HRMS 
was conducted on a Thermo electron LTQ Orbitrap XL spectrometer (Thermos, Bremen, Germany) 







   5-(6-Bromo-5-methoxy-1H-indol-3-yl)-2-(1H-pyrrol-2-yl)oxazole (3, breifussin C) 
A solution of 18 (70 mg, 0.095 mmol) in anhydrous CH2Cl2 (0.7 mL) was cooled to 0 C and 
treated with TFA (0.7 mL). The resulting mixture was stirred at rt overnight before it was 
concentrated under reduced pressure and separated between water (5 mL) and EtOAc (5 mL). The 
organic layer was washed with and saturated NaCl (3 mL), dried over MgSO4, and concentrated 
under reduced pressure. The resulting material was dissolved in anhydrous THF (1.0 mL) and 
cooled to 0 °C before it was treated with TBAF (104 µL, 1M in THF, 104 µmol). The resulting 
mixture was stirred for 20 min at 0 °C before saturated NH4Cl (5 mL) was added. The resulting 
mixture was extracted with EtOAc (2 × 5 mL) and the combined organic layers were washed with 
saturated NaCl (5 mL) and dried over MgSO4. After removal of the solvent under reduced pressure, 
the crude product was purified by flash chromatography (hexane/EtOAc, 7:3 v/v to 2:3 v/v) to give 
the title compound 3 (23 mg, 68%) as a colorless solid. Rf (hexanes/EtOAc, 1:1 v/v) = 0.25; 
1H 
NMR (500 MHz, (DMSO-d6): δ = 11.84 (s, 1H), 11.52 (d, J = 2.7 Hz, 1H), 7.82 (d, J = 2.5 Hz, 
1H), 7.70 (s, 1H), 7.54 (s, 1H), 7.43 (s, 1H), 6.98 (q, J = 2.2 Hz, 1H), 6.76 (q, J = 1.9 Hz, 1H), 6.22 
(dd, J = 3.8, 1.9 Hz, 1H), 3.96 (s, 3H); 13C NMR (126 MHz, (DMSO-d6): δ = 154.6, 150.5, 146.0, 
132.0, 124.8, 123.7, 122.1, 120.7, 120.5, 116.6, 109.8 (2C), 107.2, 104.4, 102.3, 57.1.  
 
5-(6-Bromo-4-methoxy-1H-indol-3-yl)-2-(1H-pyrrol-2-yl)oxazole (4, breitfussin D) 
A solution of 19 (51 mg, 69 µmol) in anhydrous CH2Cl2 (0.5 mL) was cooled to 0 C and treated 
with TFA (0.5 mL). The resulting mixture was stirred at rt overnight before it was concentrated 
under reduced pressure and separated between water (3 mL) and EtOAc (3 mL). The organic layer 
was washed with saturated NaCl (3 mL), dried over MgSO4, and concentrated under reduced 
pressure. The resulting material was dissolved in anhydrous THF (0.7 mL) and cooled to 0 °C 
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before it was treated with TBAF (72 µL, 1M in THF, 72 µmol). The resulting mixture was stirred 
for 20 min at 0 °C before saturated NH4Cl (4 mL) was added. The resulting mixture was extracted 
with EtOAc (2 × 4 mL) and the combined organic layers were washed with saturated NaCl (3 mL) 
and dried over MgSO4. After removal of the solvent under reduced pressure, the crude product was 
purified by flash chromatography (hexane/EtOAc, 7:3 v/v to 2:3 v/v) to give the title compound 4 
(19 mg, 77%) as a colorless solid. Rf (hexanes/EtOAc, 1:1 v/v) = 0.25; 
1H NMR (400 MHz, 
(DMSO-d6) δ = 11.80 (s, 1H), 11.71 (s, 1H), 7.74 (s, 1H), 7.35 (d, J = 2.8 Hz, 1H), 7.25 (d, J = 2.4 
Hz, 1H), 6.97 (s, 1H), 6.73 (br. s, 2H), 6.23 – 6.18 (m, 1H), 3.95 (s, 3H); 13C NMR (101 MHz, 
(DMSO-d6): δ = 154.7, 154.1, 146.2, 139.0, 123.8, 123.2, 122.0, 120.5, 115.8, 113.2, 109.8 (2C), 
108.5, 104.6, 104.4, 56.0.; HRMS (ESI): m/z M+H+ calcd for C16H13BrIN3O2
+: 358. 0186 and 
360.0165; found: 358. 0186 and 360.0164. 
 
   5-Methoxy-1-(triisopropylsilyl)-1H-indole (10) 
A solution of 5-methoxyindole (1.997 g, 13.57 mmol) in dry THF (16 mL) was added to a 
suspension of sodium hydride (843 mg, 60% w/w in mineral oil, 21.1 mmol) in THF (14 mL) at 0 
°C, and the resulting mixture was stirred at 0 °C for 1 h before TIPSCl (1.6 mL, 72.5 mmol) was 
added. The mixture was warmed to room temperature and stirred overnight (22 h), before saturated 
NH4Cl (60 mL) was added. The resulting mixture was extracted with Et2O (3 x 70 mL) and the 
combined organic layers were dried over MgSO4. After filtration and removal of the solvent in 
vacuo, the crude product was purified using flash chromatography (petroleum ether/toluene, 6:1 
v/v) to give the title compound 10 (3.818 g, 93%) as a transparent oil. 1H NMR (400 MHz, CDCl3): 
δ = 7.40 (dd, J = 9.0, 0.8 Hz, 1H), 7.23 (d, J = 3.2 Hz, 1H), 7.10 (d, J = 2.6 Hz, 1H), 6.81 (dd, J = 
9.0, 2.6 Hz, 1H), 6.56 (dd, J = 3.1, 0.8 Hz, 1H), 3.86 (s, 3H), 1.67 (sept, J = 7.5 Hz, 3H), 1.14 (d, 
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J = 7.5 Hz, 18H); 13C NMR (100 MHz, CDCl3): δ = 154.1, 135.9, 132.1, 132.0 (2C), 114.6, 111.4, 




To a solution of 10 (2.811 g, 9.26 mmol) and TMEDA (1.67 mL, 11.14 mmol) in dry THF (45 
mL) was added sec-butyl lithium (9.10, 11.10 mmol) dropwise over 20 min at -15 to -5 °C. The 
mixture was stirred for an additional 20 min at -5 °C before 1,2-dibromoethane (1.0 mL, 11.60 
mmol) was added. The resulting mixture was warmed to room temperature and stirred for 45 min 
before saturated NH4Cl (70 mL) was added and the resulting mixture was extracted with Et2O (3 x 
100 mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified using flash chromatography (petroleum ether/toluene, 6:1 v/v) to 
give a 2:3 mixture (2.363 g, 67%) of 11 and 12, from which the title compound 12 could be isolated 
as a colorless solid (496 mg, 14%) by crystallization from hexane. 1H NMR (400 MHz, CDCl3): δ  
= 7.66 (d, J = 0.9 Hz, 1H), 7.21 (d, J = 3.2 Hz, 1H), 7.12 (s, 1H), 6.54 (dd, J = 3.1, 0.9 Hz, 1H), 
3.92 (s, 3H), 1.65 (sept, J = 7.5 Hz, 3H), 1.14 (d, J = 7.5 Hz, 18H); 13C NMR (100 MHz, CDCl3): 
δ = 150.2, 136.1, 132.5, 131.4, 118.1, 106.6, 104.7, 102.5, 56.7, 18.2, 12.9; HRMS (ESI): m/z 
M+H+ calcd for C18H29BrNOSi
+: 382.1196 and 384.1176; found: 382.1198 and 384.1175. 
 
6-Bromo-3-iodo-5-methoxy-1-(triisopropylsilyl)-1H-indole (13) 
Protected bromoindole 11 (315 mg, 0.824 mmol) was dissolved in pyridine (0.5 mL) and the 
solution was cooled to 0 °C before ICl (1M in CH2Cl2, 0.90 mL, 0.90 mmol) was added slowly by 
syringe. After 15 min stirring at 0 °C, the cooling bath was removed and stirring continued for 30 
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min at rt. The reaction mixture was quenched with cold water (2 mL), diluted with ethyl acetate 
(20 mL) and HCl (1M, 3 mL) was added. The layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 20 mL), and the combined organic phase was washed with saturated 
NaCl (20 mL) before it was dried over MgSO4 and concentrated under vacuum. The residue was 
purified by flash chromatography (hexane to hexane/EtOAc, 98:2 v/v) to give the title compound 
13 (451 mg, 97%) as a colorless solid. Rf (hexane/EtOAc, 98:2 v/v) = 0.30; 
1H NMR (500 MHz, 
CDCl3): δ = 7.66 (s, 1H), 7.25 (s, 1H), 6.91 (s, 1H), 3.98 (s, 3H), 1.64 (hept, J = 7.5 Hz, 3H), 1.14 
(d, J = 7.5 Hz, 18H); 13C NMR (126 MHz, CDCl3): δ = 151.1, 136.1, 135.3, 133.0, 118.3, 108.1, 
102.7, 59.7, 56.7, 18.1, 12.8; HRMS (ESI): m/z M+H+ calcd for C18H28BrINOSi
+: 508.0163 and 
510.0142; found: 508.0161 and 510.0139. 
 
   5-(6-Bromo-5-methoxy-1-(triisopropylsilyl)-1H-indol-3-yl)oxazole (14) 
3-Iodoindole 13 (0.55 g, 1.08 mmol), K3PO4 (0.689 g, 3.25 mmol) and 2-TIPS-oxazole-5-boronic 
acid pinacol ester (456 mg, 1.30 mmol) were dissolved in water (4.0 mL) and toluene (8.0 mL) and 
the mixture was degassed. PdCl2(dppf)·CH2Cl2 (44 mg, 0.054 mmol) was added and the mixture 
was degassed with argon before it was heated at 50 °C for 2 h. The reaction mixture was cooled to 
rt, diluted with EtOAc (20 mL), filtered through a short plug of celite, added the water (20 mL) 
and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water (20 
mL), saturated NaCl (20 mL), dried over MgSO4 and concentrated under reduced pressure. The 
residue was dissolved in THF (10.0 mL) and aliquots of aqueous HCl (3 M, 2.0 mL) were added 
every 15 minutes for 1 h until the intermediate product could not be observed by TLC analysis 
(hexane/EtOAc, 4:1 v/v). The mixture was basified by addition of saturated NaHCO3 (4.0 mL), 
partitioned between water and EtOAc (20 mL). The organic layer was washed with water (15 mL) 
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and saturated NaCl (15 mL), dried over MgSO4 and evaporated under reduced pressure. The crude 
product was purified by flash chromatography (hexanes to hexanes/EtOAc, 3:1 v/v) to give the title 
compound 14 (303 mg, 62% over two steps) as a colorless thick oil. Rf (hexanes/EtOAc, 3:1 v/v) 
= 0.35; 1H NMR (500 MHz, CDCl3): δ = 7.91 (s, 1H), 7.70 (s, 1H), 7.52 (s, 1H), 7.28 (s, 1H), 7.24 
(s, 1H), 3.98 (s, 3H), 1.70 (sept, J = 7.5 Hz, 3H), 1.16 (d, J = 7.5 Hz, 18H); 13C NMR (126 MHz, 
CDCl3): δ = 151.2, 149.1, 147.7, 136.4, 130.2, 127.5, 119.7, 118.7, 107.9, 107.4, 101.7, 56.8, 18.1, 
12.8; HRMS (ESI): m/z M+H+ calcd for C21H30BrN2O2Si
+: 449.1254 and 451.1234; found: 
449.1254 and 449.1232. 
 
   5-(6-Bromo-1-(triisopropylsilyl)-1H-indol-3-yl)-2,4-iodooxazole (15) 
A solution of oxazole 14 (270 mg, 0.600 mmol) in THF (4.0 mL) was cooled to -78 °C, and 
LiHMDS (1M, 2.0 mL, 2.0 mmol) was added drop-wise and stirring continued at -78 °C for 1 h.  
A solution of iodine (305 mg, 1.20 mmol) in THF (2.0 mL) was added dropwise and stirring was 
continued at -78 °C for 30 min and then the reaction mixture was allowed to warm up to -40 °C 
and stirred for 1 h. A 10% aqueous solution of Na2S2O3 (2.0 mL) was added and the resulting 
mixture was diluted with water (20 mL) and the resulting mixture was extracted with EtOAc (3 x 
15 mL). The combined organic layers were washed with saturated NaCl (15 mL), dried over 
MgSO4 and concentrated under reduced pressure. The resulting crude product was purified using 
flash chromatography to give the title compound 15 (129 mg, 31%) as colorless solid along with a 
mixture of 2-iodooxazole 16 and 4-iodooxazole 17 (162 mg, 47%). Rf (hexanes/EtOAc, 3:1 v/v) = 
0.37; 1H NMR (500 MHz, CDCl3): δ = 7.98 (s, 1H), 7.70 (s, 1H), 7.44 (s, 1H), 3.98 (s, 3H), 1.68 
(p, J = 7.5 Hz, 3H), 1.17 (d, J = 7.5 Hz, 18H);13C NMR (126 MHz, CDCl3): δ = 156.0, 151.3, 
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135.9, 132.2, 128.0, 118.5, 108.2, 105.3, 102.6, 97.9, 77.2, 56.7, 18.1, 12.8.; HRMS (ESI): m/z 
M+H+ calcd for C21H28BrI2N2O2Si
+: 700.9187 and 702.9193; found: 701.0977 and 703.0955. 
 
   tert-Butyl 2-(5-(6-bromo-1-(triisopropylsilyl)-1H-indol-3-yl)-4-iodooxazol-2-yl)-1H-
pyrrole-1-carboxylate (18) 
To a suspension of diiodo oxazole 15 (115 mg, 0.164 mmol), N-Boc-pyrrole-2-boronic acid (52 
mg, 0.246 mmol) and Cs2CO3 (160 mg, 0.492 mmol) in 1,4-dioxane (4 mL) and water (1 mL), 
Pd(dppf)Cl2•CH2Cl2 (13 mg, 0.016 mmol) was added and the resulting solution degassed with 
argon for 10 min and then stirred at rt for 48 h. The reaction mixture was concentrated in vacuo at 
20 °C, diluted with EtOAc (15 mL) and water (10 mL). The organic layer was separated, washed 
with saturated NaCl, dried over MgSO4 and concentrated under vacuum. The crude product was 
purified by flash chromatography (hexanes/EtOAc, 5:1 v/v to 3:1 v/v) to give the title compound 
18 (80 mg, 66%) as colorless solid. Rf (hexanes/EtOAc, 3:1 v/v) = 0.25; 
1H NMR (500 MHz, 
CDCl3): δ = 8.08 (s, 1H), 7.69 (s, 1H), 7.53 (s, 1H), 7.46 (dd, J = 3.3, 1.8 Hz, 1H), 6.78 (dd, J = 
3.5, 1.8 Hz, 1H), 6.31 (t, J = 3.4 Hz, 1H), 3.92 (s, 3H), 1.69 (p, J = 7.5 Hz, 3H), 1.41 (s, 9H), 1.18 
(d, J = 7.5 Hz, 18H); 13C NMR (126 MHz, CDCl3): δ = 155.2, 151.2, 149.4, 148.5, 136.0, 132.4, 
128.1, 125.0, 120.4, 119.1, 118.4, 111.2, 108.2, 106.2, 103.3, 85.0, 76.5, 57.0, 27.9, 18.2, 12.9. 
  
    Materials and methods for bioactivity assays 
    MTS assay  
The cytotoxicities of compounds 1 – 6 were determined against the human cancer cell lines MCF-
7 (breast adenocarcinoma, American Type Culture Collection (ATCC) HTB-22), HT29 (colon 
adenocarcinoma, ATCC HTB-38), A2058 (melanoma, ATCC = CRL-11147), MDA-MB-468 
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(breast adenocarcinoma, ATCC = HTB-132), SK-BR-3 (breast adenocarcinoma, ATCC = HTB-
30), MOLT-4 (acute lymphoblastic leukemia, ATCC = CRL-1582) and MV-4-11 (biphenotypic B 
myelomonocytic leukemia, ATCC = CRL-9591), and MRC5 (non-malignant human lung 
fibroblasts, ATCC CCL-171) using the MTS assay.23 HT-29 and MOLT-4 were cultured in RPMI, 
MCF-7 and MRC-5 in E-MEM, A2058 in D-MEM, MDA-MB-468 in L15, SK-BR-3 in McCoy’s 
5A and MV-4-11 in Iscove basal medium. All cell lines were assayed in RPMI. All cells were 
incubated in 5% CO2 at 37 ˚C. When assayed, the adherent cell lines were seeded in 96-well 
microtiter plates at 2000 cells/well for MCF-7, HT-29 and A2058, 5000 cells/well for MDA-MB-
468 and SK-BR-3 and 4000 cells/well for MRC-5. After 24 h, each cancer cell line were treated 
with various concentrations of compounds 1 - 6 and incubated for 72 h. The suspension cell liens 
MOLT-4 and MV-4-11 were seeded at 10.000 cells/well and were immediately treated with various 
concentrations of compounds 1 – 6 and incubated for 72 h. The negative control was RPMI with 
1% DMSO (1% was the highest DMSO concentration used in compound wells). Positive control 
for MCF-7, HT-29, A2058 and MRC-5 was 0.5% Triton X-100 (Sigma-Aldrich). Positive control 
for MDA-MB-468, SK-BR-3, MOLT-4 and MV-4-11 was RPMI with 10% DMSO. After 72 h, 10 
µL of MTS solution (Cell Titter 96 Aqueous One Solution Reagent, Promega) was added to each 
well, and the cells were incubated for 1 h at 37 ˚C. The absorbance was measured at 485 nm using 
a DTX multimode detector (Beckman Coulter). Cell viability was calculated as follows: Cell 
survival (%) = (Absorbance treated wells – absorbance positive control)/(absorbance negative 
control – absorbance positive control) * 100. The half-maximal inhibitory concertation (IC50) was 
calculated using Graph Pad Prism software. The time dependency of the activity of 3 against HT-
29 and 4 against MCF-7 was further evaluated. Cells were added ranging concentrations of 3 and 
4 80, 60 and 36 h after seeding to evaluate the effect of the compounds after 4, 24 and 48 h exposure 
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times. Results were measured and evaluated as described above. All viability assays were 
performed in triplicate in three independent experiments.   
 
    33P-ATP filter binding kinase assay 
1, 3 and 4 were tested against 140 kinases in the Premier Screen kinase panel at the International 
Centre for Kinase Profiling using radioactive (33P-ATP) filter-binding assays.24 Compound 1 was 
tested at a concentration of 50 µM, 3 at 50, 5 and 1 µM, 4 at 5 and 1 µM. Each experiment was 
conducted in duplicates. Furthermore, the IC50 values against 13 relevant kinases were determined 
for 2 – 6. The experiments are run as a single 10-point concentration curve. 
 
    Active-site directed competition binding assay  
The binding interactions between 3 at 10 µM and 468 kinases were determined using the 
ScanMax kinase panel at DiscoverX.30, 31 In these assays, the ability of a compound to bind to the 
active site of the kinase is measures. Binding prevents the kinase from binds to an immobilized 
ligand, thereby reducing the amount of kinase captured by a solid bead. The kinases are labelled 
with a DNA tag. The amount of kinase captured by the solid bead us quantified by qPCR detecting 
the DNA tags. The binding affinities are reported as Percent of Control (% Ctrl) and are calculated 
by comparing captured kinase levels in test compound wells, negative control wells (DMSO) and 
positive control (control compounds) using the following equation: ((test compound signal – 
positive control signal)/(negative control signal – positive control signal) * 100 = % Ctrl. The 
binding constant (Kd) of 3 against 19 selected kinases were determined using KdELECT screening 
service at DiscoverX using 11-point dose response curves. Assay principle as described above. Kd 




    In vitro ATP competitiveness assay 
The compounds were diluted in 50 mM HEPES (pH 7.5), 10 mM MgCl2, 1 mM EGTA and 
0.01% Brij35. The kinase of interest (5 nM final concentration), fluorescent tracer (Invitrogen, 100 
nM final concentration) and LanthaScreen Eu-anti-GST antibody (Invitrogen, 2 nM final 
concentration) were mixed with the respective compound dilutions (from 5 nM to 10 mM) and 
incubated for 1 h. The FRET signal was quantified using an EnVision Multilabellreader 2104 
(Perkin Elmer).46 
 
    Intracellular ATP competitiveness assays 
In brief, HEK293 cells were seeded in 384 well plates and transfected with plasmids for 
expression of DRAK1 or DRAK2 fused to the NanoLuc luciferase. 24 h post transfection, cells 
were washed, permeabilized with digitonin, and treated with an ATP-competitive tracer according 
to the Manufacturer’s instructions.47  
 
   Docking 
   In brief, the binding mode of 3 into the ATP-binding pocket of PIM1 was determined by manual 
and computational docking using the Glide software from Schrödinger. Protein coordinates were 
extracted from the crystal structure of the structure of PIM1 bound to N-(5-(2-fluorophenyl)-1H-
pyrrolo[2,3-b]pyridin-3-yl)-5-((((3R,4R)-3-fluoropiperidin-4-yl)methyl)amino)pyrazolo[1,5-
a]pyrimidine-3-carboxamide (PDB code: 4K1B).  
 
   Selective cytotoxicity 
Compound 3 was assayed against the cell lines found in the OncoLead cell panel using a 
sulforhodamin B (SRB) protein staining assay technique37 (Oncolead, Karlsfeld, Germany). Cancer 
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cells (87 in total) and peripheral blood mononuclear cells (PBMCs) were assayed. Briefly, 24 h 
post seeding, cells were treated in triplicate with a 10-fold serial dilution over 10 concentrations of 
3. The highest assayed concentration was 30 µM. Following 72 h incubation, cells growth 
inhibitions were measured using SRB in a protein staining assay. Results were used to calculate 
the IC50 value of 3 against the 88 cell lines.   
 
    Polypharmacological effects 
The polypharmacological effects of 3 were evaluated using the CEREP Panlab Diversity Panel. 
The purpose of this panel of binding and cellular assays performed by CEREP is to identify a subset 
of potential receptors, transporters, ion channels, etc, for which a compound displays affinity. The 
panel includes radioligand binding- and cell based assays, which are run as described by the service 
provider. The results are expressed as percent-of-control specific binding. 
 
   In vivo toxicity against zebrafish embryos 
BioReperia (Linköping, Sweden) conducted assays to evaluate the toxicological properties of 
compound 3 against zebrafish embryos. Zebrafish embryos were produced by natural breeding 
from two males and four females, collected, screened for fertilization and moved to E4 medium. 
Embryos were incubated and at 28.5 °C. After fertilization (4 h) the embryos were allocated into 
six groups of 20 individuals. Unfertilized eggs or embryos that did not appear healthy or exhibited 
any obvious developmental defects were excluded prior to treatment onset at 4 hours after 
fertilization of the egg. The assays were conducted at five concentrations (1396, 140, 14, 1.4 and 





   Determination of ADME parameters 
   Chemical stability assay 
Chemical stability was determined by incubating test compounds at a final concentration of 2 
µM in aqueous buffer at pH 7.4 for 1, 7 and 24 h, respectively. The percentage of remaining 
compound in relation to the zero time point was calculated following LCMS-based measurement 
of sample aliquots of each time point. 
 
   Stability in cell culture medium assay 
Stability in cell culture medium was determined by incubating compound 3 at a final 
concentration of 2 µM in D-MEM supplemented with 10% fetal calf serum at pH 7.4 for 1, 7 and 
24 h, respectively. The percentage of remaining compound in relation to the zero time point was 
calculated following LCMS-based measurement of sample aliquots of each time point. 
 
   Kinetic solubility assay 
Aqueous solubility of compounds was determined by spectrophotometrical measurement of the 
kinetic solubility of a 500 µM compound solution in aqueous buffer pH 7.4 compared to a solution 
in the organic solvent acetonitrile after 90 min of vigorous shaking at room temperature. 
 
Permeability through artificial membranes assay 
Permeability through artificial membranes (PAMPA) was performed at an initial concentration 
of 500 µM of the compound in the donor compartment. After an incubation period of 20 h, 
absorption of the receiver wells was measured by spectrophotometry and permeation was 
calculated by normalization of the compound flux across a blank filter. 
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   Microsomal stability phase I assay 
Metabolic stability under oxidative conditions was measured in liver microsomes from different 
species by LCMS-based measuring of depletion of compound at a concentration of 3 µM over time 
up to 50 min at 37 °C. Based on compound half-life t1/2, in vitro intrinsic clearance CLint was 
calculated. Clint = (V x 0.693)/( t1/2 x mg) 
 
   Microsomal stability phase II assay 
Metabolic stability under conjugative conditions was measured in the glucuronidation assay by 
LCMS-based determination of % remaining of selected compounds at a concentration of 5 µM in 
incubations with liver microsomes supplemented with UDP-glucuronic acid for 1h at 37 °C. 
 
   Plasma Stability assay 
Plasma stability was measured by LCMS-based determination of % remaining of selected 
compounds at a concentration of 5 µM after incubation in 100% plasma obtained from different 
species for 1 h at 37 °C. 
 
   Plasma Protein Binding assay 
Assessment of plasma protein binding was measured by equilibrium dialysis by incubating the 
compound of interest at a concentration of 5 µM for 6 h at 37 °C in 50% plasma in buffer (v/v) 
followed by LCMS-based determination of final compound concentrations. The resulting fraction 
unbound at 50% plasma (fu50%) is extrapolated to the fraction unbound at 100% plasma (fu100%) 
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